Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain
ABSTRACTThe amino-acid composition of the immunoglobulin variable region has been observed to impact antibody pharmacokinetics (PK). Here, we sought to improve the PK of the broad HIV−1-neutralizing VRC01-class antibodies, VRC07-523LS and N6LS, by reducing the net positive charge in their variable d...
Saved in:
Main Authors: | Young D. Kwon (Author), Amarendra Pegu (Author), Eun Sung Yang (Author), Baoshan Zhang (Author), Michael F. Bender (Author), Mangaiarkarasi Asokan (Author), Qingbo Liu (Author), Krisha McKee (Author), Bob C. Lin (Author), Tracy Liu (Author), Mark K. Louder (Author), Reda Rawi (Author), Mateo Reveiz (Author), Andrew J. Schaub (Author), Chen-Hsiang Shen (Author), Nicole A. Doria-Rose (Author), Paolo Lusso (Author), John R. Mascola (Author), Peter D. Kwong (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention
by: Young D. Kwon, et al.
Published: (2021) -
Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials
by: Yunda Huang, et al.
Published: (2018) -
Removal of variable domain N-linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies
by: Gwo-Yu Chuang, et al.
Published: (2020) -
Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency
by: Baoshan Zhang, et al.
Published: (2023) -
Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants
by: Yunda Huang, et al.
Published: (2022)